Australian Covid-19 Patch outperforms Injection

In a pre-clinical study of a novel microarray vaccine patch, Vaxxas reported enhanced immune response against Covid-19. The Australian biotech company has created a small, hockey-puck shaped patch covered in a high-density 9-by-9 mm array of tiny projections in order to deliver a dry coat of the novel SARS-Cov-2 spike subunit vaccine.


The patch delivers the drug directly to the immune cells located below the skin, using microneedles that are too small to be seen by the naked eye. In this stage of research, the patch outperformed traditional injections of the vaccine, and demonstrated higher T-cell and spike-specific antibody responses.


The vaccine was shown to be stable for a minimum of 30 days after application, at 25 C. This is promising as a potential path forward to future unrefrigerated distribution, which could speed up vaccination efforts in remote or hard to reach areas where refrigeration during transport is less viable.


The leader of the study, David A. Muller, stated in an interview with Clinical Trials Arena, “Based on our results, we believe that Vaxxas’ HD-MAP could offer a compelling solution that importantly could use less vaccine and potentially could be readily distributed without refrigeration for self-administration.”


The team also believes the patch has the potential to neutralize the threat of emerging isolates, such as the recently emerging UK and South African variants of the initial Wuhan strain. The research is taking place at Queensland University in collaboration with Griffith University.


Want to learn more?

In addition to reporting clinical trial news and stories from within the patient community, we operate Citrus, a fully integrated recruitment and retention software. Citrus fits any clinical trial and simplifies the implementation of patient engagement in your clinical trial. Whether you are already working with CTMS systems or not, Citrus is the perfect add-on to make patient interaction effective.

Since 2015, our team has been hard at work raising awareness of clinical trials across the globe. A Forbes ‘30 Under 30’ company and a graduate of the renowned Techstar program in New York, Citruslabs is at the forefront of patient recruitment and retention technologies. With over 3 million patients now recorded on our databases, our patient recruitment dashboard is fast becoming the most efficient method of trial recruitment.

Now a #1 health app in 17 countries, our Mindmate app is helping to revolutionize the way we think about healthcare. Mindmate “[takes] senior care into the digital age” (Forbes, 2018) by providing people with the cognitive decline the essential tools to help them rebuild and maintain strong mental health. Trusted by millions of users, our health community continues to grow as the content available expands to the needs of individuals today.

With more than 200 research sites now using the Citrus platform to screen thousands of patients every month, researchers are now well on their way to finding new treatments for hundreds of different health conditions - something that just would not be possible without a technological solution. Make sure that your clinical trial is in the lucky 12% and turn that luck into guaranteed results with Citrus.


Check out what our customers have to say about us here.

And If you’d like to know more about how Citruslabs can help you recruit more effectively, get in touch with our team here.